立即注册找回密码

QQ登录

只需一步,快速开始

微信登录

微信扫一扫,快速登录

手机动态码快速登录

手机号快速注册登录

搜索
小桔灯网 门户 资讯中心 国际新闻 查看内容

全球癌症疾病负担组织刚刚重磅公布《全球195个国家28年29个癌症发病率,死亡率,生命 ...

2019-10-11 10:45| 编辑: 面气灵| 查看: 3818| 评论: 0|来源: Clindata

摘要: Global, Regional, and National Cancer Incidence,Mortality, Years of Life Lost, Years Lived With Disability,and Disability-Adjusted Life-Years for 29 Cancer Groups,1990 to 2017A Systematic Analysis for ...

Global, Regional, and National Cancer Incidence,
Mortality, Years of Life Lost, Years Lived With Disability,
and Disability-Adjusted Life-Years for 29 Cancer Groups,
1990 to 2017
A Systematic Analysis for the Global Burden of Disease Study

1990年至2017年全球29个癌症组的癌症发病率,死亡率,丧失生命的年限,残障生命年和经残疾调整后的生命年
对全球疾病负担研究的系统分析

中国十大癌症排行榜


2017年,中国发病率排在前10位的癌症分别为:TBL癌、胃癌、肝癌、结直肠癌、乳腺癌、非黑色素瘤皮肤癌、食管癌、其他恶性肿瘤、前列腺癌、脑和中枢神经系统癌症,如图所示。

图:2017年中国发病率前十位的癌症

死亡率排在前10位的癌症分别为:TBL癌、肝癌、胃癌、食管癌、结直肠癌、乳腺癌、胰腺癌、其他恶性肿瘤、脑和中枢神经系统癌症和前列腺癌。


图:2017年中国死亡率前十位的癌症

IMPORTANCE
Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.
OBJECTIVE
To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning.
EVIDENCE REVIEW
We used the GBD study estimation methods to describe cancer incidence,mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate.We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence.
FINDINGS
In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority ofcancer DALYs came from years of life lost (97%), and only 3%came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach
cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs).
CONCLUSIONS AND RELEVANCE
The national epidemiological profiles of cancer burden in the
GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

重要性
癌症和其他非传染性疾病(NCD)现在被广泛认为是对全球发展的威胁。联合国非传染性疾病最新高级别会议重申了这一观点,并强调了在实现2011年《关于预防和控制非传染性疾病的政治宣言》和第三个可持续发展目标方面进展缓慢。缺乏情况分析,确定优先重点和预算是实现这些目标的主要障碍。所有这些共同点在于,它们需要有关当地癌症流行病学的信息。全球疾病负担(GBD)研究具有独特的优势,可以提供这些关键数据。
目的
描述1990年至2017年间195个国家的29个癌症组的癌症负担,以提供癌症控制规划所需的数据。
证据审查
我们使用GBD研究估算方法来描述癌症发生率,死亡率,残障生存年限,生命损失年限以及残障调整生命年(DALYs)。结果在国家一级以及社会人口统计学指数(SDI)上进行显示,该指标是收入,教育程度和总生育率的综合指标。我们还分析了流行病学与人口学转变对癌症发病率的影响。
发现
2017年,全球有2450万例癌症事件(1680万例无非黑色素瘤皮肤癌[NMSC])和960万例癌症死亡。大多数癌症DALY来自失去生命的岁月(97%),只有3%来自患有残疾的岁月。男女患低SDI的几率最低(七分之一),高SDI的几率最高(二分之一)。2017年,男性最常见的事件癌症是NMSC(430万起事件);气管,支气管和肺癌(TBL)(150万起事故);和前列腺癌(130万起事件)。男性最常见的癌症死亡和DALY原因是TBL癌(130万死亡和2840万DALY),肝癌(572 000死亡和1520万DALY)和胃癌癌症(542 000例死亡和1220万DALYs)。对于2017年的女性而言,最常见的事件癌症是NMSC(330万事件),乳腺癌(190万事件)和大肠癌(819 000事件)。女性癌症死亡和DALY的主要原因是乳腺癌(601 000例死亡和1740万DALYs),TBL癌(596 000例死亡和1260万DALYs)和结直肠癌(414 000例死亡和830DALYs)。
结论与关联
全国癌症流行病学概况
GBD研究显示出巨大的异质性,这反映了不同的风险因素,经济环境,生活方式以及获得医疗和筛查的机会。政策制定者和其他利益相关者可以使用GBD研究来制定和改善国家和地方癌症控制,以实现全球目标并提高癌症治疗的公平性。Cancer is nowwidely recognized as a global problem that unfortunately lacks a global solution. The latest United Nations high-level meeting on noncommunicable diseases (NCDs) exemplified this conundrum. Despite global commitment to reducing the risk of and disability from NCDs,including cancer, implementation of knownsolutions is inadequate to reach the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases(25% reduction in premature mortality from NCDs by 2025) and the third Sustainable Development Goal (by 2030 reduce by onethird premature mortality from NCDs through prevention and treatment, and promote mental health and well-being).To reduce cancer burden, identifying the scope of the problem and mapping out implementation of solutions is best done in National Cancer Control Plans (NCCPs). However, a recent review showed that only 29% of low-income countries had a NCCP, and even if NCCPs existed, cost, financing, monitoring,and expansion of information systems was often inadequate.Many highly effective prevention and treatment strategies exist for cancer.However, they are often very specific (eg,vaccination forhumanpapillomavirus and hepatitisBvirus for prevention of cervical and liver cancer, or tyrosine kinase inhibitors for cancerswith targetablemutations). Effective NCCPs therefore require detailed knowledge about the local burden of cancer and associated risk factors. We herein present results from the Global Burden of Disease (GBD) 2017 study describing cancer incidence, mortality, years of life lost (YLLs), years livedwith disability (YLDs), and disability-adjusted lifeyears (DALYs) for 195 countries from1990 through 2017, which can inform cancer control through policy, resource allocation,and health system planning.癌症已被广泛认为是一个全球性问题,但不幸的是缺乏全球性解决方案。最近的联合国非传染性疾病高级别会议就是这一难题的例证。尽管全球致力于降低包括癌症在内的非传染性疾病的风险和致残性,但已知解决方案的实施仍不足以达成2011年《关于预防和控制非传染性疾病的政治宣言》(到2025年使非传染性疾病的过早死亡减少25%)和第三次可持续发展。发展目标(到2030年,通过预防和治疗将非传染性疾病的过早死亡率降低三分之一,并促进心理健康和福祉)。减少癌症负担,确定问题的范围并规划解决方案的实施最好在国家癌症中心控制计划(NCCP)。然而,最近的一项审查表明,只有29%的低收入国家拥有NCCP,即使存在NCCP,信息系统的成本,融资,监控和扩展也常常不足。许多有效的癌症预防和治疗策略存在但是,它们通常非常具体(例如,人乳头瘤病毒和乙型肝炎病毒的疫苗接种,以预防子宫颈癌和肝癌,或酪氨酸激酶抑制剂用于具有可靶向突变的癌症)。因此,有效的NCCP需要有关癌症局部负担和相关风险因素的详细知识。我们在此提供了2017年全球疾病负担(GBD)研究的结果,该研究描述了1990年至2017年间195个国家的癌症发病率,死亡率,生命损失年限(YLLs),残疾寿命年限(YLDs)和残疾调整生命年(DALYs)。可以通过政策,资源分配和卫生系统规划来告知癌症控制。Methods
Methods have remained similar to the GBD 2016 study.Detailed descriptions of the methods can be found in theGBD 2017 publications as well as in the eAppendix, eFigures, and eTables in the Supplement.For eachGBDstudy, the entire time series is re-estimated. This study therefore supersedes prior GBD iterations. The GBD study is compliant with the Guidelines forAccurate and TransparentHealth EstimatesReporting statement (eTable 1 in the Supplement). Compared with the prior GBD study (GBD 2016), the neoplasms category for GBD 2017 also includes benign and in situ neoplasms (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] codes D00-D49). Because
disability associatedwithbenign neoplasms is most often very small,we only estimated disability for the new cause:myelodysplastic,
myeloproliferative, and other hematopoietic neoplasms.The terms malignant neoplasms or cancer in this article only include ICD-10 codes C00 through C96. Other changes since GBD 2016 are the addition of new data sources(eTable 3 in the Supplement) for GBD 2017 and improvements in the way we estimated cancer survival by using the mortality-to-incidence ratio (MIR). In this study, estimates are presented for 29 cancer categories and 195 countries and territories.Estimates for benign neoplasms as well as selected subnational estimates are available online (https://vizhub.
healthdata.org/gbd-compare/ andhttp://ghdx.healthdata.org/
gbd-results-tool). All rates are reported per 100000 personyears.
The GBD world population standard was used for the calculation of age-standardized rates.9 We report 95% uncertainty intervals for all estimates.方法
方法仍与GBD 2016研究相似,有关方法的详细说明可在GBD 2017出版物以及增刊中的eAppendix,eFigures和eTables中找到。对于每个GBD研究,将重新估算整个时间序列。因此,本研究取代了先前的GBD迭代。GBD研究符合《准确和透明的健康估计报告指南》声明(补编中的表1)。与之前的GBD研究(GBD 2016)相比,GBD 2017的肿瘤类别还包括良性和原位肿瘤(《国际疾病和相关健康问题统计分类》,第十次修订[ICD-10]代码D00-D49)。因为与良性肿瘤相关的残疾通常很小,我们仅估计新病因的残疾:骨髓增生异常,骨髓增生性和其他造血肿瘤。本文中的术语“恶性肿瘤或癌症”仅包括ICD-10代码C00至C96。自GBD 2016以来的其他变化是为GBD 2017添加了新的数据源(补编中的表3),并通过使用死亡率与发病率(MIR)来估计癌症存活率的方式有所改进。在这项研究中,给出了针对195个国家和地区的29种癌症类别的估计值,有关良性肿瘤的估计值以及部分国家以下估计值可在线获得(https:// vizhub.healthdata.org/gbd-compare/和http://ghdx.healthdata.org/gbd-results-tool)。所有费率均按每100000人年报告。GBD世界人口标准用于计算年龄标准化率。9我们报告所有估计的不确定性区间为95%。


Estimation Framework
The GBD cancer estimation process starts with mortality.Mortality estimates are made based on vital registration system(83% of data), cancer registry (16% of data) (eTable 3 in the Supplement), and verbal autopsy data (1% of data) using an ensemble model approach.9,10 Predictive covariates used in the model can be found in the eAppendix (eTable 8 in the Supplement). Single-cause mortality estimates are scaled into the separately estimated all-cause estimate.9 To estimate cancer incidence, mortality estimates are divided by a separately estimated MIR for each cancer type, sex, 5-year age group, location, and year; additional information regarding incidence and MIR estimation can be found in the eAppendix and eFigure2 inthe Supplement.Data sources used for estimatingMIRs
are described in eTable 2 in the Supplement. MIRs allowfor a uniform method to estimate incidence. Other cancer estimation frameworks11,12 have set a precedent for using MIRs for decades and have detailed its benefits, including greater representativeness,
especially in settings that lack quality or complete population-based cancer registry systems. By determining incidence using mortality, we are able to account for uncaptured incident cases and, if mortality and incidence are determined correctly, estimating incidence based on MIRs should result in the similar results if using incidence directly.
The correlation between survival data and the MIR is used to estimate 10-year cancer prevalence. Total prevalence is partitioned
into 4 sequelae: (1) diagnosis/treatment, (2) remission,(3) metastatic/disseminated, and (4) terminal phase.Each sequela prevalence is multiplied by a disability weight to estimate YLDs. Lifetime prevalence of procedure-related disability is estimated for larynx, breast, colorectal, bladder, and prostate cancers. A standard life expectancy is used to estimate years of life lost (YLLs).9 DALYs are the sum of YLDs and YLLs. To determine the contribution of population aging,population growth, and change in age-specific rates on the change in incident cases between 2007 and 2017, we use
hypothetical demographic scenarios holding 2 of these 3 components
constant. Results are stratified by quintiles of Sociodemographic
Index (SDI), which is a composite indicator including fertility, education, and income.


估算框架
GBD癌症评估过程始于死亡率,死亡率评估是基于生命登记系统(数据的83%),癌症登记(数据的16%)(补编中的表3)和口头尸检数据(数据的1%)进行的。9,10该模型中使用的预测协变量可以在eAppendix中找到(补编中的eTable 8)。单因死亡率估算被缩放为单独估算的全因估算。9为了估算癌症发生率,将死亡率估算除以每种癌症类型,性别,5岁年龄组,位置和年份的单独估算的MIR;有关发病率和MIR估计的其他信息,请参见附录中的eAppendix和eFigure2。用于估计MIR的数据源附录中的eTable 2中对此进行了说明。MIR允许使用统一的方法来估计发生率。其他癌症评估框架[11,12]为使用MIR提供了数十年的先例,并详细说明了其好处,包括提高代表性,特别是在缺乏质量或缺乏完整的基于人群的癌症登记系统的环境中。通过使用死亡率确定发病率,我们可以考虑未捕获的事件病例,如果正确确定了死亡率和发病率,那么如果直接使用发病率,则基于MIR估算发病率应该会得出相似的结果。生存数据与MIR之间的相关性用于估计10年癌症患病率。总患病率划分分为4个后遗症:(1)诊断/治疗,(2)缓解,(3)转移/扩散和(4)末期。每个后遗症患病率乘以残疾权重以估算YLD。估计与手术相关的残疾的终生流行率适用于喉癌,乳腺癌,结直肠癌,膀胱癌和前列腺癌。使用标准预期寿命来估计丧失的年限(YLL)。9DALY是YLD和YLL的总和。为了确定2007年至2017年间人口老龄化,人口增长以及特定年龄比率的变化对突发事件变化的影响,我们使用假设的人口统计情景,包含这三个组成部分中的两个不变。结果按社会人口统计学的五分位数分层

声明:
1、凡本网注明“来源:小桔灯网”的所有作品,均为本网合法拥有版权或有权使用的作品,转载需联系授权。
2、凡本网注明“来源:XXX(非小桔灯网)”的作品,均转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责。其版权归原作者所有,如有侵权请联系删除。
3、所有再转载者需自行获得原作者授权并注明来源。

鲜花

握手

雷人

路过

鸡蛋

最新评论

关闭

官方推荐 上一条 /3 下一条

客服中心 搜索 官方QQ群 洽谈合作